First study of agenT-797, botensilimab (BOT) and balstilimab (BAL) in gastroesophageal cancer shows disease control rate (DCR) in 77% of patients ...
STORM Therapeutics raises $56M Series C and doses first patient in Phase 2 sarcoma trial of STC-15, the world’s first RNA ...
STORM Therapeutics, a Cambridge-based clinical stage company targeting RNA modifications to reprogram cells and develop novel ...
The proceeds will support the advancement of STC-15 in a Phase 2 study in select sarcoma indicationsFirst‑in‑class METTL3 inhibitor reprograms ...
Texas Instruments Incorporated (TXN) is transitioning from a heavy investment phase to a period of margin expansion and ...
Hair loss in women is driven by complex interactions between hormonal changes, hair follicle biology, and the hair growth ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results